88 related articles for article (PubMed ID: 16252122)
1. An autologous system for culturing head and neck squamous cell carcinomas for the assessment of cellular therapies on the chorioallantois membrane.
Gronau S; Thess B; Riechelmann H; Fischer Y; Schmitt A; Schmitt M
Eur Arch Otorhinolaryngol; 2006 Apr; 263(4):308-12. PubMed ID: 16252122
[TBL] [Abstract][Full Text] [Related]
2. Trifunctional bispecific antibody-induced tumor cell lysis of squamous cell carcinomas of the upper aerodigestive tract.
Gronau SS; Schmitt M; Thess B; Reinhardt P; Wiesneth M; Schmitt A; Riechelmann H
Head Neck; 2005 May; 27(5):376-82. PubMed ID: 15818557
[TBL] [Abstract][Full Text] [Related]
3. [T-cells activated with a trifunctional bi-specific antibody in head and neck cancer].
Gronau S; Schmitt M; Reinhardt P; Wiesneth M; Riechelmann H
Laryngorhinootologie; 2005 Nov; 84(11):822-8. PubMed ID: 16358189
[TBL] [Abstract][Full Text] [Related]
4. Lymphokine-activated killing of autologous and allogeneic short-term cultured head and neck squamous carcinomas.
Leess FR; Bredenkamp JK; Lichtenstein A; Mickel RA
Laryngoscope; 1989 Dec; 99(12):1255-61. PubMed ID: 2601539
[TBL] [Abstract][Full Text] [Related]
5. Human cytotoxic T-cell lines with restricted specificity for squamous cell carcinoma of the head and neck.
Yasumura S; Hirabayashi H; Schwartz DR; Toso JF; Johnson JT; Herberman RB; Whiteside TL
Cancer Res; 1993 Mar; 53(6):1461-8. PubMed ID: 8443824
[TBL] [Abstract][Full Text] [Related]
6. [Adoptive immunotherapy by intra-arterial infusion of ATLAK or Allo-TLAK cells in patients with head and neck cancer].
Ikawa T; Eura M; Fukiage T; Murakami H; Yamasaki S; Fukuda K; Fukushima M; Arishima S; Maehara T; Ishikawa T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1438-47. PubMed ID: 2786378
[TBL] [Abstract][Full Text] [Related]
7. p53 as an immunotherapeutic target in head and neck cancer.
Hoffmann TK; Bier H; Donnenberg AD; Whiteside TL; De Leo AB
Adv Otorhinolaryngol; 2005; 62():151-60. PubMed ID: 15608425
[TBL] [Abstract][Full Text] [Related]
8. Antitumor immunization of head and neck squamous cell carcinoma patients with a virus-modified autologous tumor cell vaccine.
Herold-Mende C; Karcher J; Dyckhoff G; Schirrmacher V
Adv Otorhinolaryngol; 2005; 62():173-83. PubMed ID: 15608427
[TBL] [Abstract][Full Text] [Related]
9. Angiogenesis induced by head and neck squamous cell carcinoma xenografts in the chick embryo chorioallantoic membrane model.
Petruzzelli GJ; Snyderman CH; Johnson JT; Myers EN
Ann Otol Rhinol Laryngol; 1993 Mar; 102(3 Pt 1):215-21. PubMed ID: 7681273
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma.
Nakano H; Kishida T; Asada H; Shin-Ya M; Shinomiya T; Imanishi J; Shimada T; Nakai S; Takeuchi M; Hisa Y; Mazda O
J Gene Med; 2006 Jan; 8(1):90-9. PubMed ID: 16097036
[TBL] [Abstract][Full Text] [Related]
11. [Effect of lymphokine-activated killer cells of head and neck tumors in vitro and in nude mice].
Duan DS
Zhonghua Er Bi Yan Hou Ke Za Zhi; 1993; 28(5):281-3, 314. PubMed ID: 8192930
[TBL] [Abstract][Full Text] [Related]
12. Viable head and neck tumor spheroids stimulate in vitro autologous monocyte MCP-1 secretion through soluble substances and CD14/lectin-like receptors.
Olsnes C; Heimdal JH; Kross KW; Olofsson J; Aarstad HJ
Eur Arch Otorhinolaryngol; 2005 Dec; 262(12):953-60. PubMed ID: 16328410
[TBL] [Abstract][Full Text] [Related]
13. Generation of an autologous cell system for immunotherapy of squamous cell carcinoma of the head and neck.
Mayer A; Andratschke M; Pauli C; Graefe H; Kristina K; Wollenberg B
Anticancer Res; 2005; 25(6B):4075-80. PubMed ID: 16309201
[TBL] [Abstract][Full Text] [Related]
14. Injury to autologous normal tissues and tumors mediated by lymphokine-activated killer (LAK) cells generated in vitro from peripheral blood mononuclear cells of glioblastoma patients.
Fujimiya Y; Suzuki Y; Katakura R; Ohno T
J Hematother; 1999 Feb; 8(1):29-37. PubMed ID: 10192299
[TBL] [Abstract][Full Text] [Related]
15. Effect of suicide gene therapy in combination with immunotherapy on antitumour immune response & tumour regression in a xenograft mouse model for head & neck squamous cell carcinoma.
Ambade AV; Joshi GV; Mulherkar R
Indian J Med Res; 2010 Oct; 132():415-22. PubMed ID: 20966520
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of therapeutic potential of interleukin 2-expanded tumor-infiltrating lymphocytes in squamous cell carcinoma of the head and neck.
Boscia R; Chen K; Johnson JT; Whiteside TL
Ann Otol Rhinol Laryngol; 1988; 97(4 Pt 1):414-21. PubMed ID: 3261562
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for head and neck squamous cell carcinoma.
Li Q; Prince ME; Moyer JS
Oral Oncol; 2015 Apr; 51(4):299-304. PubMed ID: 25624094
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic therapy of head and neck squamous cell carcinoma by vascular endothelial growth factor antisense therapy.
Riedel F; Götte K; Hörmann K; Grandis JR
Adv Otorhinolaryngol; 2005; 62():103-20. PubMed ID: 15608422
[TBL] [Abstract][Full Text] [Related]
19. [Immunotherapy for head and neck squamous cell carcinoma].
Bron L; Romero P
Rev Med Suisse; 2006 Oct; 2(81):2216-9. PubMed ID: 17076151
[TBL] [Abstract][Full Text] [Related]
20. [Immunotherapy: a new alternative treatment for head and neck squamous cell carcinoma].
Bron L; Romero P
Bull Cancer; 2007 Sep; 94(9):793-7. PubMed ID: 17878099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
